Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

NCT02063997 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout

Interventions

DRUG: Arhalofenate 600 mg
DRUG: Allopurinol 300 mg
DRUG: Colchicine 0.6 mg
DRUG: Placebo
DRUG: Arhalofenate 800 mg

Sponsor

Gilead Sciences